(Nva2)-cyclosporine--less potent than cyclosporine A in rats with lung and heart transplants.
The ability of a new cyclosporine (Cs) derivative, (Nva2)-Cs (CsG), to suppress rejection of lung and heart allografts in rats was determined and compared with that of CsA. Left lungs were transplanted orthotopically; hearts were transplanted heterotopically into the abdomen. (Nva2)-Cs was used in three experimental protocols: (1) single or three (Nva2)-Cs injections given to lung-transplanted rats, (2) daily oral (Nva2)-Cs treatment at different doses compared with similar CsA treatments in heart allografted rats, and (3) An 11-day (Nva2)-Cs treatment starting at increasing intervals after transplantation of hearts. (Nva2)-Cs was found to be immunosuppressive, and effective even when the treatment started as late as four days after transplantation. However, (Nva2)-Cs was less effective than CsA in suppressing rejection of lung and heart allografts at low doses. Because (Nva2)-Cs is possibly not nephrotoxic, it might be a useful drug if used in higher doses than CsA or in combination with other immunosuppressive agents.
D000818:Animals; D016572:Cyclosporine; D003524:Cyclosporins / Q000097:blood / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006084:Graft Rejection / Q000187:drug effects*; D016027:Heart Transplantation; D016041:Heart-Lung Transplantation; D016040:Lung Transplantation; D008297:Male; D051381:Rats; D011912:Rats, Inbred ACI / Q000276:immunology; D011914:Rats, Inbred BN / Q000276:immunology; D011917:Rats, Inbred Lew / Q000276:immunology
D003524:Cyclosporins; C045571:cyclosporin G; D016572:Cyclosporine